Damora Therapeutics, Inc.
DMRA
$24.16
$1.074.63%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 4.07M | 1.74M | 1.96M | 1.92M | 1.70M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 27.39M | 3.16M | 3.42M | 2.60M | 2.71M |
| Operating Income | -27.39M | -3.16M | -3.42M | -2.60M | -2.71M |
| Income Before Tax | -200.69M | -3.13M | -3.43M | -2.53M | -6.75M |
| Income Tax Expenses | 44.00K | -- | 4.00K | 2.00K | -8.00K |
| Earnings from Continuing Operations | -200.74M | -3.13M | -3.44M | -2.53M | -6.74M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -200.74M | -3.13M | -3.44M | -2.53M | -6.74M |
| EBIT | -27.39M | -3.16M | -3.42M | -2.60M | -2.71M |
| EBITDA | -27.38M | -3.15M | -3.42M | -2.59M | -2.70M |
| EPS Basic | -135.60 | -2.36 | -2.60 | -1.92 | -5.13 |
| Normalized Basic EPS | -11.14 | -1.48 | -1.62 | -1.20 | -1.09 |
| EPS Diluted | -135.60 | -2.36 | -2.60 | -1.92 | -5.13 |
| Normalized Diluted EPS | -11.14 | -1.48 | -1.62 | -1.20 | -1.09 |
| Average Basic Shares Outstanding | 1.48M | 1.33M | 1.32M | 1.32M | 1.31M |
| Average Diluted Shares Outstanding | 1.48M | 1.33M | 1.32M | 1.32M | 1.31M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |